News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Rights issue in PledPharma oversubscribed

May 24, 2013

PledPharma AB
Company Announcement

Rights issue in PledPharma oversubscribed

Stockholm, 2013-05-24 14:00 CEST (GLOBE NEWSWIRE) -- 
PledPharmas rights issue with subscription period from 6 May to 20 May 2013 was
oversubscribed by 38 percent. PledPharma receives approximately SEK 18.6
million before issue costs. 

The rights issue was subscribed to approximately 95 percent with preferential
rights and the remaining 5 percent were subscribed for without preferential
rights. The new share issue was, thus, fully subscribed. Shares subscribed for
without preferential rights, will be allocated to shareholders who exercised
subscription rights in relation to the number of existing subscription rights
used by each shareholder. 

“The oversubscription shows great interest in PledPharma and PledOx®. The
rights issue is done to expand PLIANT study with more study centers worldwide
to ensure implementation, and also to achieve greater flexibility and time to
implement the best possible licensing deal for PledPharma drug candidate
PledOx. With these measures, we believe that we can get the "top line" results
from the study by mid-2014”, says CEO Jacques Näsström. 

PledPharma recently announced that IMS Consulting Group is appointed as adviser
for the out-licensing of PledOx, which starts in 2013. 

The rights issue will increase the number of shares by 1.687.314 to a total of
21.935.089 shares and the share capital will increase by SEK 88.806 to SEK

After registration of the share capital increase at the Companies Registration
Office, the paid interim shares in the rights issue will be converted into new
shares. Trading in the new shares is expected to commence on NASDAQ OMX First
North when the new shares are registered in the subscriber's VP account or
deposit account. 

For further information please contact:

Jacques Näsström, CEO PledPharma, phone +46 73 713 09 79

Michaela Johansson, CFO PledPharma, phone +46 70 926 17 75

About PledPharma
PledPharma is a Swedish specialty pharma company that develops PledOx® for
prevention of severe chemotherapy-induced side effects in cancer patients. Due
to these side effects optimal treatment cannot be carried out. The current
market for supportive cancer care is some SEK 72 billion. PledOx protects
normal cells against oxidative stress. It belongs to a group of compounds named
lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese
SuperOxide Distmutase (MnSOD) – the most important endogenous cellular
protectant against devastating oxidative stress. Oxidative stress is a
condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of
chemotherapy treatment. The company is also evaluating opportunities of using
PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10